|
Jan. 06, 2021 |
|
|
Feb. 05, 2025 |
|
|
jRCT2031200286 |
ONO-4578-04:Phase 1 study of ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX in subjects with metastatic pancreatic cancer(ONO-4578-04) |
|
ONO-4578-04:ONO-4578 Phase 1 Study |
Namba Yoshinobu |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
||
Center Information Medical |
||
Ono Pharmaceutical Co.,LTD |
||
3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan |
||
+81-120-626-190 |
||
clinical_trial@ono-pharma.com |
Complete |
Jan. 16, 2021 |
||
| Jan. 13, 2021 | ||
| 60 | ||
Interventional |
||
non-randomized controlled trial |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
1. Pancreatic invasive ducatal adenocarcinoma |
||
1. Patients with severe complication |
||
| 20age old over | ||
| No limit | ||
Both |
||
metastatic pancreatic cancer |
||
ONO-4578 given as combinations of ONO-4578, ONO-4538 and modified FOLFIRINOX or Gem/nab-PTX |
||
Safety, tolerability |
||
| Ono Pharmaceutical Co.,LTD |
| Kanagawa Cancer Center Institutional Review Board | |
| 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa | |
+81-45-520-2222 |
|
| Approval | |
Dec. 28, 2020 |
No |
| NCT06538207 |
none |